… , tissue engineered products, and combined advanced therapies are regulated as medicinal
products from 2007 onward and formally defined as advanced therapy medicinal products (…

… assessment (HTA) bodies. Advanced therapy medicinal products (ATMPs) represent a …
These products are based on genes, tissues, or cells, commonly developed as one-shot …

… a reality of genuinely personalised medicine. There are … technology and uncertainty over
the use of real-world evidence induce caution among clinicians, health technology assessment …

… Health Technology Assessment (… assessing the value of new pharmaceutical products,
namely, the improvement in length and quality of life, ease of use, and cost-savings to the health …

… evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for
Health … However, conventional methods of health technology appraisal employed by the UK …

… improve efficiency in resource allocation is Health Technology Assessment (HTA). The use
… and it is now used to assess and appraise the value of new medical technologies as well as …

… Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously
untreatable and high-burden diseases. Expectations are high and active company pipelines …

… Although health technology assessment (HTA) systems base their decision making process
either on economic evaluations or comparative clinical benefit assessment, a central aim of …

… It is these combined uncertainties, together with pressure to deliver the health technology
assessment (HTA) for the ATMP soon after regulatory licensing, that is causing payers and …

… a reality of genuinely personalised medicine. There are … technology and uncertainty over
the use of real-world evidence induce caution among clinicians, health technology assessment …